- Current report filing (8-K)
25 Junho 2010 - 6:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported):
June 24,
2010
Interleukin
Genetics, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State or
Other Jurisdiction of Incorporation)
|
001-32715
|
|
94-3123681
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
135
Beaver Street Waltham, MA
|
|
02452
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(781)
398-0700
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
|
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item
3.01
Notice of Delisting or Failure to
Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On June
24, 2010, Interleukin Genetics, Inc. (the “Company”) received a notice from NYSE
Amex LLC (the “Exchange”) notifying the Company that it had failed to regain
compliance with Section 1003(a)(iii) of the Exchange’s Company Guide due to
stockholders’ equity of less than $6,000,000 and losses from continuing
operations and/or net losses in its five most recent fiscal years.
The
notice indicates that unless the Company requests a hearing before a Listings
Qualifications Panel, its common stock will be delisted. The Company intends to
request such a hearing, which will defer any delisting action until the panel
renders a decision following the hearing. The Company’s common stock will
continue to trade on the NYSE Amex in the interim. There can be no assurance
that following the hearing the panel will grant the Company’s request for
continued listing.
On June
25, 2010, the Company issued a press release to report the receipt of the notice
from the Exchange. A copy of that press release is attached to this
Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein
by reference.
Item
9.01 Financial
Statements and Exhibits.
(d)
Exhibits
.
|
Exhibit
Number
|
|
Description of Exhibit
|
|
99.1
|
|
Press
release dated June 25, 2010.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
Interleukin
Genetics, Inc.
|
|
|
|
(Registrant)
|
|
|
|
|
|
Date:
June 25, 2010
|
|
/s/
ELIOT M. LURIER
|
|
|
|
Eliot
M. Lurier
|
|
|
|
Chief
Financial Officer
|
|
|
|
(Signature)
|
Interleukin Genetics (AMEX:ILI)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Interleukin Genetics (AMEX:ILI)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
